Full-Time
Senior Manager
Amazon & Retail Media
Posted on 3/3/2026
Seed Health
201-500 employees
Develops and sells probiotic microbiome products
Compensation Overview
$150k - $170k/yr
Remote in USA
Remote
 Growth & Marketing (1) |
|---|
- 7+ years of experience in a performance marketing role with 5+ years of experience focused on Amazon
- Deep experience in Amazon Sponsored Ads and DSP, including hands-on experience in one or both of these channels
- Owned a 7-figure retail media budget for an omni-channel consumer packaged goods business, with a deep understanding of how to drive new to brand customer acquisition and Subscribe & Save performance across Amazon’s entire ecosystem
- Deep understanding of how to enhance retail media performance with Amazon Marketing Cloud, including multi-touch measurement, new to brand performance, and path to purchase analyses
- Ability to translate back and forth between tactical and strategic communication, understanding how nuanced tactics within retail media ladder up to Seed’s broader performance objectives
- Experience managing and holding agencies accountable to performance targets
- Experience in non-Amazon retail media networks, such as Walmart Connect, Roundel, Instacart, etc.
- The expectation for this role is a 50%/50% split between strategic and tactical focus.
- From a tactical lens, this role will oversee our agency partners to ensure excellence in execution, while personally owning forecasting, spend pacing, reporting, and incrementality modeling.
- Examples of strategic work include ownership of the test and learn roadmap, go-to-market planning for new product launches, and partnering with cross-functionals on retail media initiatives (i.e. creative optimization, media mix modeling, etc), among other items.
- This individual will be the go-to subject matter expert for Amazon and future retail media channels, possessing superior core skills while demonstrating an ability to identify root cause issues and solve ambiguous, complex problems through cross-functional collaboration and impact.
- This role is a strategic owner rather than just an executor; this individual will help Seed define its core media KPIs across SKUs and channels that ladder up to overall business performance. This individual should go beyond “what happened”, but help us understand “what would happen if”.
- This role acts as a force multiplier - this individual should know how to extract 110% value from our agency partners in order to focus on the 3-6 month strategic horizon.
- This role will report to the Sr. Director, Amazon
Seed Health develops and sells probiotic and microbiome-based consumer products for humans and pets through its online store. Formulations are grounded in scientific research, tested for safety and effectiveness, and shipped directly to customers. The company differentiates itself by pairing rigorous science with education and transparent communication, while pursuing a direct-to-consumer model and a broader focus on planetary health. Its goal is to improve human and planetary health by making microbiome science actionable and accessible for everyday wellness.
Company Size
201-500
Company Stage
Series A
Total Funding
$40M
Headquarters
Los Angeles, California
Founded
2016
Simplify's Take
What believers are saying
- 500% revenue growth past three years; top-five Amazon probiotic and Target fastest-growing brand.
- Expanded omnichannel distribution to Target, Amazon, and Sprouts nationwide by September 2024.
- Clinical pipeline expansion: DS-01® efficacy in antibiotic recovery, IBS, and metabolic health demonstrated.
What critics are saying
- FDA enforcement actions on unapproved health claims for DS-01® and VS-01® within 12 months.
- Pendulum Therapeutics' GLP-1 mimicking probiotic directly competes on butyrate pathways with superior data.
- Resilient Soils Project fails to yield patentable PFAS-degrading microbes; SeedLabs funding halted.
What makes Seed Health unique
- DS-01® clinically proven to increase Urolithin A production 100-fold by Day 7.
- Multi-strain synbiotics validated through double-blind, placebo-controlled trials at academic institutions.
- Proprietary microbial genomics and whole-genome sequencing for strain validation and quality assurance.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Seed Health who can refer or advise you
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Company Match
Mental Health Support
Wellness Program
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↑ 1%DS-01® is the first broad-spectrum synbiotic clinically shown to increase production of both Urolithin A and butyrate—two key microbial metabolites linked to whole-body healthPresented at Digestive Disease Week® (DDW) 2025, the findings expand DS-01®'s clinical foundation and reinforce the potential of microbiome-targeted products to impact multiple biological systemsBOSTON, May 5, 2025 /PRNewswire/ -- Microbiome science company Seed Health presented clinical data on its flagship innovation, DS-01® Daily Synbiotic, at Digestive Disease Week® (DDW) 2025. Findings from a randomized, placebo-controlled clinical trial in healthy adults demonstrated that DS-01® increased production of two key microbial metabolites—Urolithin A and butyrate—implicated in gut barrier function, metabolism, and healthy aging. The trial also found reductions in C-Reactive Protein (CRP), a widely used marker of systemic inflammation, suggesting DS-01®'s potential to influence immune pathways. The findings underscore DS-01®'s impact beyond microbial composition, demonstrating measurable biological function through the production of microbiome-mediated metabolites.The company presented two posters during the "Prebiotics, Probiotics and Synbiotics in Health and Disease" session.Presentation HighlightsEffects of a novel, broad-spectrum synbiotic on Urolithin A production: A randomized, placebo-controlled clinical trialThis randomized, placebo-controlled clinical trial evaluated DS-01® for its ability to increase production of Urolithin A—a microbiome-derived metabolite linked to mitochondrial function, cellular energy, metabolic health, intestinal barrier integrity, and healthy aging. DS-01® provides the natural machinery to produce Urolithin A, delivering both a polyphenol precursor in its prebiotic outer capsule and key microbes in its probiotic inner capsule.Overall, this is the first study to demonstrate that a broad-spectrum synbiotic can increase Urolithin A production in humans. Key findings include:Rapid and Sustained Urolithin A Increase: DS-01® increased urinary Urolithin A levels by approximately 100-fold by Day 7 (P<0.0001), with levels sustained through Day 91.DS-01® increased urinary Urolithin A levels by approximately 100-fold by Day 7 (P<0.0001), with levels sustained through Day 91
(In fact, one of its editors previously covered the Daily Synbiotic at The Chalkboard Mag) But it wasn't until Seed Health launched its VS-01(TM) Vaginal Synbiotic that I decided to give the brand a try to rebalance my microbiome and the rest of my system.
The study, which is the first to show that a multi-strain vaginal synbiotic can establish a protective vaginal environment, will be presented at the Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG)The data demonstrate that VS-01™ successfully cultivates a vaginal microbiome dominated by Lactobacillus crispatus, reduces harmful microbes, and combats vaginal dysbiosisThese results underscore the potential of the vaginal microbiome and microbiome-directed innovations to redefine standards of care in women's healthBOSTON, Aug. 1, 2024 /PRNewswire/ -- Seed Health will present new clinical data on its flagship vaginal microbiome innovation, VS-01™ Vaginal Synbiotic, at the upcoming 2024 Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting. Data from a randomized, placebo-controlled clinical trial demonstrated the superior efficacy of VS-01™ in cultivating a stable and healthy vaginal microbiome. The synbiotic successfully established a protective environment dominated by Lactobacillus crispatus and inhibited harmful microbes associated with vaginal dysbiosis and inflammation. These findings highlight the transformative potential of proactive, preventive care centered on the vaginal microbiome, shifting the focus from traditional symptom management to maintaining a balanced and resilient vaginal ecology.A landmark 2012 study from vaginal microbiome researcher Jacques Ravel, Ph.D., demonstrated that the most stable and optimal vaginal microbiome is characterized by a dominance of the bacterium Lactobacillus crispatus, which plays a protective role in maintaining vaginal health. However, everyday factors such as menstruation, sexual activity, exercise, stress, contraceptives, and cleansers can deplete the abundance of L
LA-based probiotic company Seed is launching a new vaginal suppository that will help women maintain a more stable vaginal microbiome.
An optimal vaginal microbiome is a key driver of gynecological, urogenital, and reproductive healthVS-01™ is a multi-strain probiotic and prebiotic clinically validated to establish an optimal vaginal microbiome and sustain regulated vaginal pHBuilt on the research of renowned vaginal microbiome scientist Dr. Jacques Ravel, VS-01™ is the first to pioneer a microbial genomics approach powered by the most comprehensive host-microbiome vaginal data setLOS ANGELES, May 21, 2024 /PRNewswire/ -- Seed Health , a microbiome science company, today launched VS-01™ Vaginal Synbiotic, the first vaginal synbiotic clinically validated to rapidly establish an optimal vaginal microbiome dominated by Lactobacillus crispatus, the vagina's most protective bacteria. Dr. Jacques Ravel's pioneering research has elucidated the crucial role of the vaginal microbiome in gynecological, urogenital, and reproductive health, though everyday factors like stress, sex, menstruation, and diet can disrupt its equilibrium and deplete the abundance of L. crispatus. Dr